Clinical Trial Update: A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

This document reports an update on a Phase 1/2 study evaluating KW-2478 in combination with bortezomib for relapsed and/or refractory multiple myeloma, with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• KW-2478

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-11-05